0404. Interferons

9 Herpesviral [herpes simplex] infections B01 91 Basal cell carcinoma C44
9 Cytomegaloviral disease [CMV] B34 9 Kaposi's sarcoma [AIDS-associated] C64

Interferons

Ann Arbor, MI: Truven Health Analytics Micromedex; updated periodically.

23
Interferons
Adjuvant interferon in high-risk melanoma: The AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma
Interferons
99 Other specified and unspecified types of non-Hodgkin lymphoma C86
Interferons
81 Anal high risk human papillomavirus HPV DNA test positive R87
Kao JH, Chen PJ, Lai MY, Chen DS Herrine SK, Brown R Jr, Esposito S, et al
Interferons -- expanding therapeutic roles The preferred alternatives are as follows:• 569 Stenosis of lacrimal punctum H11

Interferons

Pegasys is not recommended in patients with known cases of hypersensitivity to peginterferon or any of its components.

11
Interferons
Last changes made May 24, 2018
Interferons
Biojector 2000 is considered a medically necessary acceptable alternative to conventional needle and syringes for members with exacerbating-remitting MS who can not safely use needles for self-injection due to tremors and decreased coordination
Interferons
who are experiencing benefit from therapy as evidenced by disease stability or disease improvement
Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-n-1
Treatment consisted of six CHVP cycles administered monthly, followed by an additional six cycles administered every 2 months for 1 year Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: A randomized trial

Interferons

42 Hairy cell leukemia C92.

16
Interferons
Persons with genotype 1 had less benefit from retreatment
Interferons
Targeting interferons and their pathways in systemic lupus erythematosus
Interferons
All remaining phase III trial patients in the active and control groups are being transitioned into an open-label clinical trial in which all patients receive IFN gamma-1b to track longer-term outcomes with IFN gamma-1b for a minimum of 1 year